• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用数据链接对英格兰乙型和丙型肝炎死亡率进行敏感性分析:达到世界卫生组织的死亡率消除阈值

Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality.

作者信息

Powell Annabel A, Costella Annastella, Roche Rachel, Leeman David, Brown Ashley, Emmanouil Beatrice, Gillyon-Powell Mark, Harris Ross, Mitchell Holly D, Simmons Ruth, Desai Monica

机构信息

Blood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.

Department of Hepatology, Imperial College London, Imperial College NIHR BRC, London, UK.

出版信息

J Viral Hepat. 2025 Apr;32(4):e70016. doi: 10.1111/jvh.70016.

DOI:10.1111/jvh.70016
PMID:40135930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11938805/
Abstract

The United Kingdom, along with many other countries, is working towards eliminating viral hepatitis as a public health threat by 2030, with a combined mortality target of less than or equal to six deaths per 100,000 population. The current methodology of reporting uses death registrations alone, which has been estimated to underestimate mortality rates by up to 60% for hepatitis C (HCV)-related liver disease. We aim to conduct a sensitivity analysis using data linkage of death certificates, hepatitis B (HBV) and HCV diagnoses and admissions for end-stage liver disease (ESLD) and/or hepatocellular carcinoma (HCC) to estimate mortality rates, assess progress towards elimination and evaluate underreporting. Between 2000 and 2023, 7967 deaths were reported due to HBV- and/or HCV-associated ESLD and/or HCC. Using data linkage of all three datasets, this increased to 11,487, with underreporting estimated to be 37% overall. The upper bound combined mortality rate was estimated to be 1.3 deaths per 100,000 population at its peak in 2015, therefore surpassing the WHO target for all years evaluated. From 2015 to 2023, both HCV-associated ESLD and/or HCC mortality decreased (1.12 to 0.88 deaths per 100,000 population), however, there was a slight increase for HBV-associated ESLD and/or HCC deaths during the same time frame (0.3 to 0.35). A higher proportion of HBV-related deaths were in males (p < 0.05) who died outside London (p < 0.05) and a lower proportion were White (p < 0.05) when compared to HCV-related deaths. While England has met the WHO impact targets, it is important we continue to drive reductions in mortality.

摘要

英国与许多其他国家一道,正努力到2030年消除病毒性肝炎这一公共卫生威胁,设定的综合死亡率目标为每10万人口死亡人数小于或等于6人。目前的报告方法仅使用死亡登记数据,据估计,这会使丙型肝炎(HCV)相关肝病的死亡率低估高达60%。我们旨在利用死亡证明、乙型肝炎(HBV)和HCV诊断以及终末期肝病(ESLD)和/或肝细胞癌(HCC)入院数据的关联进行敏感性分析,以估计死亡率、评估消除工作进展并评估报告不足情况。2000年至2023年期间,报告了7967例因HBV和/或HCV相关的ESLD和/或HCC导致的死亡。通过对所有三个数据集进行数据关联,这一数字增至11487例,总体报告不足估计为37%。2015年峰值时,上限综合死亡率估计为每10万人口1.3例死亡,因此在所有评估年份均超过了世界卫生组织的目标。2015年至2023年期间,HCV相关的ESLD和/或HCC死亡率均有所下降(从每10万人口1.12例降至0.88例),然而,同期HBV相关的ESLD和/或HCC死亡人数略有增加(从0.3例增至0.35例)。与HCV相关死亡相比,HBV相关死亡中男性比例更高(p<0.05),在伦敦以外地区死亡的比例更高(p<0.05),白人比例更低(p<0.05)。虽然英格兰已实现世界卫生组织的影响目标,但我们继续推动死亡率下降仍很重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d068/11938805/54a019d3765a/JVH-32-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d068/11938805/a95084c8dfbc/JVH-32-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d068/11938805/54a019d3765a/JVH-32-0-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d068/11938805/a95084c8dfbc/JVH-32-0-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d068/11938805/54a019d3765a/JVH-32-0-g001.jpg

相似文献

1
Sensitivity Analysis of Hepatitis B and C Mortality in England Using Data Linkage: Meeting the WHO Elimination Threshold for Mortality.利用数据链接对英格兰乙型和丙型肝炎死亡率进行敏感性分析:达到世界卫生组织的死亡率消除阈值
J Viral Hepat. 2025 Apr;32(4):e70016. doi: 10.1111/jvh.70016.
2
Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England.利用数据链接监测英格兰丙型肝炎相关终末期肝病和肝细胞癌的住院情况。
J Viral Hepat. 2020 Jan;27(1):20-27. doi: 10.1111/jvh.13203. Epub 2019 Oct 3.
3
Liver-related mortality among people with hepatitis B and C: Evaluation of definitions based on linked healthcare administrative datasets.乙型肝炎和丙型肝炎患者的肝脏相关死亡率:基于关联医疗行政数据集的定义评估。
J Viral Hepat. 2023 Jun;30(6):520-529. doi: 10.1111/jvh.13824. Epub 2023 Mar 10.
4
Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA - descriptive analysis and estimation of 2015 baseline.欧盟/欧洲经济区乙型和丙型肝炎导致的肝病死亡率——描述性分析和 2015 年基线估计。
Infect Dis (Lond). 2020 Sep;52(9):625-637. doi: 10.1080/23744235.2020.1766104. Epub 2020 Jun 17.
5
Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma.病毒性肝炎相关肝细胞癌死亡率和资源利用的独立预测因素
Ann Hepatol. 2017 Jul-Aug;16(4):555-564. doi: 10.5604/01.3001.0010.0290.
6
Hepatitis B and C viruses and survival from hepatocellular carcinoma in the Arkhangelsk region: a Russian registry-based study.阿尔汉格尔斯克地区乙型和丙型肝炎病毒与肝细胞癌患者生存率:一项基于俄罗斯登记处的研究
Int J Circumpolar Health. 2013 May 13;72:20282. doi: 10.3402/ijch.v72i0.20282. Print 2013.
7
Burden of virus-associated liver cancer in the Arab world, 1990-2010.1990 - 2010年阿拉伯世界病毒相关性肝癌负担
Asian Pac J Cancer Prev. 2015;16(1):265-70. doi: 10.7314/apjcp.2015.16.1.265.
8
Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort.乙型肝炎病毒和丙型肝炎病毒相关肝细胞癌的临床表现及预后比较:一项全国队列分析
PLoS One. 2014 Nov 5;9(11):e112184. doi: 10.1371/journal.pone.0112184. eCollection 2014.
9
Death certificates compared to SEER-Medicare data for surveillance of liver cancer mortality due to hepatitis B or hepatitis C infection.与 SEER-Medicare 数据相比,死亡证明可用于监测乙型肝炎或丙型肝炎感染导致的肝癌死亡率。
J Viral Hepat. 2021 Jun;28(6):934-941. doi: 10.1111/jvh.13498. Epub 2021 Mar 28.
10
Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales.新南威尔士州乙肝报告人群中失代偿期肝硬化和肝细胞癌的发病趋势
JHEP Rep. 2022 Aug 6;4(10):100552. doi: 10.1016/j.jhepr.2022.100552. eCollection 2022 Oct.

本文引用的文献

1
Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection (Text Extract): Executive Summary.慢性乙型肝炎感染者预防、诊断、照护及治疗指南(文本摘录):执行摘要
Infect Dis Immun. 2024 Jul;4(3):103-105. doi: 10.1097/ID9.0000000000000128. Epub 2024 Jun 12.
2
Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia.澳大利亚新南威尔士州病毒性肝炎肝脏相关发病率和死亡率的趋势。
Lancet Reg Health West Pac. 2024 Aug 31;51:101185. doi: 10.1016/j.lanwpc.2024.101185. eCollection 2024 Oct.
3
Association of hepatitis B virus treatment with all-cause and liver-related mortality among individuals with HBV and cirrhosis: a population-based cohort study.
乙肝病毒治疗与乙肝和肝硬化患者全因死亡率及肝脏相关死亡率的关联:一项基于人群的队列研究
Lancet Reg Health Am. 2024 Jun 28;36:100826. doi: 10.1016/j.lana.2024.100826. eCollection 2024 Aug.
4
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.2022年全球乙型肝炎的流行率、照护流程及预防覆盖率:一项建模研究
Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879-907. doi: 10.1016/S2468-1253(23)00197-8. Epub 2023 Jul 27.
5
Global Patterns and Trends in Total Burden of Hepatitis B from 1990 to 2019 and Predictions to 2030.1990年至2019年全球乙肝总负担的模式与趋势及到2030年的预测
Clin Epidemiol. 2022 Dec 14;14:1519-1533. doi: 10.2147/CLEP.S389853. eCollection 2022.
6
Favorable impact in hepatitis C-related mortality following free access to direct-acting antivirals in Spain.在西班牙免费提供直接作用抗病毒药物后对丙型肝炎相关死亡率产生的有利影响。
Hepatology. 2022 May;75(5):1247-1256. doi: 10.1002/hep.32237. Epub 2021 Dec 17.
7
Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.聚乙二醇干扰素-free DAA 治疗方案在 HCV 感染失代偿期肝硬化患者中的应用及死亡率降低的证据。
J Viral Hepat. 2021 Sep;28(9):1246-1255. doi: 10.1111/jvh.13543. Epub 2021 Jul 8.
8
Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis.直接作用抗病毒方案对慢性丙型肝炎患者死亡率和发病率结局的影响:系统评价和荟萃分析。
J Viral Hepat. 2021 May;28(5):739-754. doi: 10.1111/jvh.13482. Epub 2021 Feb 20.
9
Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016.2008 年至 2016 年英格兰丙型肝炎病毒(HCV)感染者死亡率:一项观察性队列研究。
Euro Surveill. 2019 Jul;24(30). doi: 10.2807/1560-7917.ES.2019.24.30.1800695.
10
Causes of death among persons diagnosed with hepatitis C infection in the pre- and post-DAA era in England: A record linkage study.在英国,丙型肝炎感染患者在 DAA 时代前后的死亡原因:一项记录链接研究。
J Viral Hepat. 2019 Jul;26(7):873-880. doi: 10.1111/jvh.13096. Epub 2019 Apr 23.